#######################
# Document Properties #
#######################
SET DOCUMENT Licenses    = "MIT License"
SET DOCUMENT ContactInfo = "farah.humayun@scai-extern.fraunhofer.de"

SET DOCUMENT Name        = "heme_24904418.bel"
SET DOCUMENT Version     = "1.0.2"
SET DOCUMENT Authors     = "Farah Humayun"
SET DOCUMENT Description = "Heme BEL model is a disease model based on Biological Expression Language (BEL) containing the core mechanisms of heme as modulator in Hemolytic diseases such as sickle-cell anemia, beta-thalassemia, malaria and autoimmune hemolytic anemia."

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns"
DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns"
DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns"
# DEFINE NAMESPACE FB           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/80171ae62cf43aa1fc8a6c326b94537ab342458c/external/fb-names.belns"
DEFINE NAMESPACE HBP            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/export/hbp-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns"
DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns"
DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns"
DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns"
DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns"
DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns"
DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns"
DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns"
DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns"
DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns"

# Namespaces hosted on https://arty.scai.fraunhofer.de/artifactory/bel/namespace
# ------------------------------------------------------------------------------
DEFINE NAMESPACE CTO            AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns"
DEFINE NAMESPACE DO             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns"
DEFINE NAMESPACE HP             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns"
DEFINE NAMESPACE SCOMP          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns"
DEFINE NAMESPACE SFAM           AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"

DEFINE NAMESPACE HM        AS PATTERN ".*"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN ".*"
DEFINE ANNOTATION TimePoint     AS PATTERN ".*"
DEFINE ANNOTATION Concentration     AS PATTERN ".*"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############

SET Citation = {"PubMed", "Front Pharmacol. 2014 May 27;5:115. doi: 10.3389/fphar.2014.00115. eCollection 2014.", "24904418"}

SET TextLocation = "Review"

SET Evidence = "Importantly, heme b interaction with heme oxygenase
(HO; Lad et al., 2003), the enzyme responsible for heme intracellular
catabolism, and hemopexin (Hx; Paoli et al., 1999), a plasmatic
heme scavenger, is essential for the regulation of free heme availability
and Fe recycling (Kovtunovych et al., 2010; Tolosano et al.,
2010)."

p(HGNC:HMOX1) pos deg(a(CHEBI:heme))
p(HGNC:HPX) -| a(CHEBI:heme) 

SET Evidence = "Besides its physiological importance, heme has a potent oxidative
capacity oxidizing lipids (Tappel, 1953, 1955; Vincent et al.,
1988) and proteins (Aft and Mueller, 1984; Vincent, 1989), and
damaging DNA (Aft and Mueller, 1983)."

a(CHEBI:heme) pos bp(MESH:"Lipid Peroxidation")
a(CHEBI:heme) pos bp(GO:"protein oxidation")
a(CHEBI:heme) neg a(CHEBI:"deoxyribonucleic acid")

SET Evidence = "The consequences
of heme toxicity can be appreciated in hemolytic diseases such
as Î²-thalassemia, sickle-cell disease (SCD), ischemia-reperfusion
(IR), and malaria (Katori et al., 2002; Pamplona et al., 2007;Vinchi
et al., 2013)."

a(CHEBI:heme) pos path(MESH:"beta-Thalassemia")
a(CHEBI:heme) pos path(MESH:"Anemia, Sickle Cell")
a(CHEBI:heme) pos path(MESH:"Reperfusion Injury")
a(CHEBI:heme) pos path(MESH:Malaria)

SET Evidence = "Because of its large
molecular size, this complex is maintained in the intravascular
space, preventing the association of otherwise free Hb with nitric
oxide (NO; Reiter et al., 2002) and inhibiting the release of free
heme (Melamed-Frank et al., 2001)."

a(MESH:"haptoglobin-hemoglobin complex") neg p(HGNC:HBB)

SET Evidence = ". In the presence of
reactive oxygen species (ROS), Hb is oxidized to methemoglobin
(MetHb; Balla et al., 1993), characterized by the change in the
oxidative state of the Fe present in the heme molecule from ferrous
(Fe+2) to ferric (Fe+3)."

a(MESH:"Reactive Oxygen Species") pos rxn(reactants(p(HGNC:HBB)), products(a(CHEBI:methemoglobin)))

SET Evidence = "Hx inhibits
the oxidative property of heme (Eskew et al., 1999) and mediates
heme transportation to intracellular compartments through
the macrophage receptor CD91 (Hvidberg et al., 2005), a critical
step on heme catabolism."

p(HGNC:HPX) -| bp(GO:"heme oxidation")
p(HGNC:LRP1) -> bp(GO:"heme catabolic process")

SET Evidence = "Once inside the cells, heme is catabolized
by HO enzymes, generating equimolar amounts of biliverdin,
carbon monoxide (CO), and Fe (Tenhunen et al., 1968). "

p(HGNC:HMOX1) pos bp(GO:"heme catabolic process")
bp(GO:"heme catabolic process") -> a(MESH:Biliverdine)
bp(GO:"heme catabolic process") -> a(CHEBI:"carbon monoxide")
bp(GO:"heme catabolic process") -> a(CHEBI:"iron(2+)")

SET Evidence = " Differently
from biliverdin and CO, which have anti-inflammatory
effects (Otterbein et al., 2000; Baranano et al., 2002), free Fe is
highly oxidative and can promote free radicals generation through
the Fenton reaction, which catalyzes hydroxyl radicals from the
reaction of Fe with H2O2 (Fenton, 1894)."

a(MESH:Biliverdine) -| bp(GO:"inflammatory response") 
a(CHEBI:"carbon monoxide") -| bp(GO:"inflammatory response") 
a(CHEBI:"iron(2+)") pos a(MESH:"Free Radicals")
rxn(reactants(a(CHEBI:"iron(2+)"), a(CHEBI:"hydrogen peroxide")), products(a(MESH:"Hydroxyl Radical")))

SET Evidence = "Cells deficient on FtH are more susceptible
to oxidative damage, while increased amounts of FtH protects
cells from death induced by challenges such as Fe, tumor necrosis
factor (TNF), heme, heme plus TNF, or oxidized low-density
lipoprotein (LDL; Juckett et al., 1995; Pham et al., 2004; Gozzelino
et al., 2012)."

p(HGNC:FTH1) -| bp(MESH:"Oxidative Stress")
p(HGNC:FTH1) -| p(HGNC:TNF)
p(HGNC:FTH1) -| a(CHEBI:"iron(2+)")
p(HGNC:FTH1) -| a(CHEBI:heme)
p(HGNC:FTH1) -| a(CHEBI:"oxidised LDL")

SET Evidence = ". Heme can destabilize biological
membranes increasing its permeability and the chance of
lysis (Schmitt et al., 1993), as it happens with erythrocytes (Chiu
and Lubin, 1989)."

SET Cell = "erythrocyte"
a(CHEBI:heme) -> bp(GO:"positive regulation of membrane permeability")

SET Evidence = "Once intercalated into cellular
plasma membranes heme amplifies cellular susceptibility to
oxidative-mediated injury by oxidants such as H2O2 or those
derived from activated inflammatory cells (Balla et al., 1991a,b,
1993)."

a(CHEBI:heme) -> a(CHEBI:hydroperoxide)
a(CHEBI:"hydrogen peroxide") -> bp(MESH:"Oxidative Stress")

SET Evidence = "Furthermore, heme induces
ROS generation dependent on enzymatic reactions."

a(CHEBI:heme) -> a(MESH:"Reactive Oxygen Species")

SET Evidence = "Alternatively, heme induced
formation of radical species relies on the conversion of
low-reactive organic hydroperoxides (ROOH) into highly reactive
alkoxyl (ROâ¢) and peroxyl (ROOâ¢) radicals (Tappel, 1953, 1955;
Van der Zee et al., 1996)."

a(CHEBI:heme) -> rxn(reactants(a(CHEBI:hydroperoxide)), products(a(MESH:"alkoxyl radical"), a(CHEBI:hydroperoxyl)))

SET Evidence = " These radicals may initiate further lipid
peroxidation forming alkyl radicals that in the presence of O2
form more peroxyl radicals leading to a facile propagation of free
radical reactions."

a(MESH:"alkoxyl radical") -> bp(MESH:"Lipid Peroxidation")
a(CHEBI:hydroperoxyl) -> bp(MESH:"Lipid Peroxidation")

SET Evidence = " Heme injection in mice leads to vascular
permeability, leukocyte migration from the intravascular environment
to tissues and increase of acute-phase proteins (Lyoumi et al.,
1999; Wagener et al., 2001b), hallmarks of acute inflammation."

a(CHEBI:heme) pos bp(GO:"regulation of vascular permeability")
a(CHEBI:heme) pos bp(GO:"leukocyte migration involved in inflammatory response")

SET Evidence = "Heme activates endothelial cells inducing the expression of the
adhesion molecules ICAM-1 (intercellular adhesion molecule 1),
VCAM-1 (vascular cell adhesion molecule 1), E-selectin, Pselectin,
and von Willebrand factor (VWF; Wagener et al., 1997;
Belcher et al., 2014) and causes neutrophil migration (GraÃ§aSouza
et al., 2002; Porto et al., 2007). "

a(CHEBI:heme) -> bp(GO:"endothelial cell activation")
a(CHEBI:heme) -> p(MGI:Icam1)
a(CHEBI:heme) -> p(MGI:Vcam1)
a(CHEBI:heme) -> p(HGNC:SELE)
a(CHEBI:heme) -> p(HGNC:SELP)
a(CHEBI:heme) -> p(MGI:Vwf)
a(CHEBI:heme) -> bp(GO:"neutrophil migration")

SET Evidence = "A seminal study demonstrated that the ability
of heme to activate neutrophils depend on protein kinase C
(PKC) activation and ROS generation, inducing the expression of
adhesion molecules and modifying actin cytoskeleton dynamics,
necessary features for neutrophils migration (GraÃ§a-Souza et al.,
2002)."

a(CHEBI:heme) -> bp(GO:"neutrophil migration")
a(MESH:"Protein Kinase C") -> bp(GO:"neutrophil migration")
a(MESH:"Reactive Oxygen Species") -> bp(GO:"neutrophil migration")

SET Evidence = "In fact, heme can induce neutrophil migration by acting
as a chemotactic molecule (Porto et al., 2007) or by inducing
the production of leukotriene B4 (LTB4) by macrophages (Monteiro
et al., 2011)."

a(CHEBI:"leukotriene B4") -> bp(GO:"neutrophil migration")

SET Evidence = "Heme-induced neutrophils activation leads to
extracellular traps (NETs) release through a mechanism dependent
on ROS generation (Chen et al., 2014). "

a(CHEBI:heme) -> bp(GO:"neutrophil activation")
bp(GO:"neutrophil activation") pos a(MESH:"Extracellular Traps")

SET Evidence = "Although neutrophils have important
functions controlling infection, these cells can promote
vascular and tissue injury by generating ROS, secreting proteases,
and releasing extracellular chromatin (NETs; reviewed in
MÃ³csai, 2013)."

a(MESH:Neutrophils) -| path(MESH:Infection)
a(MESH:Neutrophils) pos a(MESH:"Reactive Oxygen Species")

SET Evidence = "In this context, heme inhibits
neutrophils apoptosis, increasing their longevity, and possibly
enhancing harmful stimuli from these cells (Arruda et al., 2004,
2006)."

a(CHEBI:heme) -| bp(GO:"neutrophil apoptotic process")

SET Evidence = "Moreover, IL-1Î²
and TNF modifies the hypothalamus threshold of the body temperature
causing fever."

p(HGNC:TNF) pos path(MESH:Fever)
p(HGNC:IL1B) pos path(MESH:Fever)

SET Evidence = " KC (keratinocyte-derived chemokine) is
a chemokine that attracts neutrophils to sites of inflammation
and LTB4 is a lipid mediator that functions as a chemoattractant
molecule and also activates leukocytes."

a(CHEBI:"leukotriene B4") -> act(a(MESH:Leukocytes))

SET Evidence = ". Heme activates
macrophages inducing the production of TNF, KC (Figueiredo
et al., 2007), IL-1Î² (unpublished), and LTB4 (Monteiro et al.,
2011)."

a(CHEBI:heme) -> p(HGNC:TNF)
a(CHEBI:heme) -> p(HGNC:IL1B)
a(CHEBI:heme) -> a(CHEBI:"leukotriene B4")

SET Evidence = " Although KC and IL-1Î² functions were not investigated
during heme-induced inflammatory effects, TNF and LTB4 were
described as essential inflammatory mediators during inflammatory
events induced by heme."

p(HGNC:TNF) -> path(MESH:Inflammation)
p(HGNC:IL1B) -> path(MESH:Inflammation)

SET Evidence = " As described before, LTB4 has an
important function regulating heme-induced neutrophils migration
(Monteiro et al., 2011)."

a(CHEBI:"leukotriene B4") -> bp(GO:"neutrophil migration")
a(CHEBI:heme) -> bp(GO:"neutrophil migration")

SET Evidence = "On the other hand, TNF secretion
induced by heme is essential for the activation of the programed
necrotic cell death pathway, which is denominated necroptosis
(Fortes et al., 2012)."

a(CHEBI:heme) -> p(HGNC:TNF)
p(HGNC:TNF) -> bp(GO:"necroptotic process")

SET Evidence = "Hemoglobin is used as a nutrient by Plasmodium, the protozoan
parasite that causes malaria, during its replication stage inside erythrocytes
in the course of the infection in mammals (Francis et al.,
1997)."

a(MESH:Plasmodium) pos path(MESH:Malaria)

SET Evidence = " Similarly to heme, Hz also induces the production of
several inflammatory mediators by macrophages such as cytokines
and chemokines, and induces leukocytes migration (reviewed
by Olivier et al., 2014)."

a(MESH:hemozoin) -> a(MESH:Cytokines)
a(MESH:hemozoin) -> a(MESH:Chemokines)
a(MESH:hemozoin) -> bp(GO:"leukocyte migration")

SET Evidence = "These concepts challenged the idea that
the cytotoxic and inflammatory effects of heme were exclusively
mediated by the oxidative capability of the Fe associated with the
amphipathic property of the porphyrin ring."

a(CHEBI:"iron(2+)") -> path(MESH:Inflammation)

SET Evidence = "In fact, hemolysis
or heme injection in Hxâ/â mice cause increased inflammation
and severe renal damage compared to wild type (WT)
mice (Tolosano et al., 1999; Vinchi et al., 2008). "

p(HGNC:HPX) -| path(MESH:Inflammation)
p(HGNC:HPX) -| path(MESH:"Kidney Diseases")

SET Evidence = "Mice lacking
HO-1 (Hmox1â/â) are highly susceptible to pathologic conditions
associated with increased serum heme concentration."

p(MGI:Hmox1) -| a(CHEBI:heme)

SET Evidence = "For
instance, Hmoxâ/â mice develops acute renal failure and marked
mortality when submitted to rhabdomyolysis, a pathological condition
that increases serum myoglobin which can be oxidized
and release heme (Nath et al., 2000). "

SET MeSHDisease = "Rhabdomyolysis"
p(MGI:Hmox1) neg path(MESH:"Acute Kidney Injury")

SET MeSHAnatomy = "Serum"
path(MESH:Rhabdomyolysis) pos p(MGI:Mb)

SET Evidence = " Furthermore, Hmox1â/â
mice are susceptible to liver IR which is characterized by tissue
damage in sites that are reperfused after ischemia injury
and hemolysis (Devey et al., 2009)."

SET MeSHAnatomy = "Liver"
p(MGI:Hmox1) neg path(MESH:"Insulin Resistance")

SET Evidence = " SCD and Î²-thalassemia are genetic diseases
associated to erythrocytes that are prone to lysis due to
defective Hb production (Heinle and Read, 1948; Pauling et al.,
1949; Ingram, 1957; discussed later). "

path(MESH:"Anemia, Sickle Cell") pos path(MESH:Hemolysis)
path(MESH:"beta-Thalassemia") pos path(MESH:Hemolysis)

SET Evidence = " CO inhibits Hb oxidation and subsequently heme
release, thus blocking heme accumulation in serum and preventing
heme from exerting its inflammatory effects in the course
of malaria disease (Ferreira et al., 2011)."

SET MeSHDisease = "Malaria"
a(CHEBI:"carbon monoxide") -| a(CHEBI:heme)
a(CHEBI:heme) -> path(MESH:Inflammation)

SET Evidence = "During the resolution phase of
inflammation HO-1 expression in leukocytes reduces adhesion
molecules expression and leukocytes migration, thus contributing
to wound healing (Wagener et al., 2003a). "

SET Cell = "leukocyte"
p(HGNC:HMOX1) -| a(MESH:"Cell Adhesion Molecules")
p(HGNC:HMOX1) -| bp(GO:"leukocyte migration")
p(HGNC:HMOX1) -> bp(MESH:"Wound Healing")

SET Evidence = "Highly purified heme free
of endotoxin contamination was used, as well as polymyxin B,
anti-TLR4/MD2, and lipid A antagonist, all of which inhibited
the effects of LPS but did not interfere with the induction of
TNF by heme."

a(CHEBI:heme) -> p(RGD:Tnf)

SET Evidence = "The TLR4 activates
two distinct pathways: MyD88 and TRIF. In macrophages, heme
induces a biased MyD88 activation and the secretion of the
pro-inflammatory cytokines TNF and KC."

p(HGNC:TLR4) -> p(HGNC:MYD88)
p(HGNC:TLR4) -> p(HGNC:TICAM1)
a(CHEBI:heme) -> p(HGNC:MYD88)
a(CHEBI:heme) -> p(HGNC:TNF)
a(CHEBI:heme) -> a(MESH:"keratinocyte-derived chemokines")

SET Evidence = "TLR4 activation leads to
MAPKs and NFÎºB activation, which are necessary to TNF secretion."

p(HGNC:TLR4) -> a(MESH:"Mitogen-Activated Protein Kinases")
p(HGNC:TLR4) -> p(HGNC:NFKB1)
p(HGNC:NFKB1) -> p(HGNC:TNF)
a(MESH:"Mitogen-Activated Protein Kinases") -> p(HGNC:TNF)

SET Evidence = "Heme induces ROS generation independently of TLR4."

a(CHEBI:heme) -> a(MESH:"Reactive Oxygen Species")

SET Evidence = "However, ROS
is necessary to induce TNF secretion and MAPK activation."

a(MESH:"Reactive Oxygen Species") -> p(HGNC:TNF)
a(MESH:"Reactive Oxygen Species") -> a(MESH:"Mitogen-Activated Protein Kinases")

SET Evidence = " mROS scavenger
(Mito-TEMPO) and NADPH oxidases inhibitors (apocynin and DPI) block
TNF production induced by heme."

a(CHEBI:TEMPO) -| p(HGNC:TNF)
a(CHEBI:apocynin) -| p(HGNC:TNF)
a(CHEBI:dibenziodolium) -| p(HGNC:TNF)

SET Evidence = "WhileMAPK8 increases ROS
generation, TNF induces RIP1âRIP3 necrosome which triggers necroptosis."

p(HGNC:MAPK8) -> a(MESH:"Reactive Oxygen Species")
p(HGNC:TNF) -> act(p(HGNC:RIPK1))
p(HGNC:TNF) -> act(p(HGNC:RIPK3))
p(HGNC:RIPK1) -> bp(GO:"necroptotic process")
p(HGNC:RIPK3) -> bp(GO:"necroptotic process")

SET Evidence = "mROS scavenger (Mito-TEMPO) and NADPH oxidases inhibitors (apocynin
and DPI) block heme-induced necroptosis."

a(CHEBI:TEMPO) -| bp(GO:"necroptotic process")
a(CHEBI:apocynin) -| bp(GO:"necroptotic process")
a(CHEBI:dibenziodolium) -| bp(GO:"necroptotic process")

SET Evidence = "Moreover, HO-1 has a protective effect
during heme-induced necroptosis."

a(CHEBI:heme) -> bp(GO:"necroptotic process")
p(HGNC:HMOX1) -| bp(GO:"necroptotic process")

SET Evidence = "Heme induces Syk phosphorylation in macrophages."

SET Cell = "macrophage"
a(CHEBI:heme) -> p(HGNC:SYK, pmod(Ph)) 

SET Evidence = " Heme amplifies cytokines induced by cell surface
receptors (TLR2, TLR4, TLR5), endosome receptors (TLR3, TLR9), and
cytosolic receptors (NOD1 and NOD2)."

a(CHEBI:heme) -> a(MESH:Cytokines)
a(CHEBI:heme) -> p(HGNC:TLR2)
a(CHEBI:heme) -> p(HGNC:TLR4)
a(CHEBI:heme) -> p(HGNC:TLR5)
a(CHEBI:heme) -> p(HGNC:TLR9)
a(CHEBI:heme) -> p(HGNC:TLR2)
a(CHEBI:heme) -> p(HGNC:NOD1)
a(CHEBI:heme) -> p(HGNC:NOD2)

SET Evidence = "Moreover, heme amplifies MyD88-
(TNF and IL-6) and TRIF-dependent (IP-10) cytokines."

a(CHEBI:heme) -> p(HGNC:TNF)
a(CHEBI:heme) -> p(HGNC:IL6)
a(CHEBI:heme) -> p(HGNC:CXCL10)

SET Evidence = "During intravascular hemolysis the serum proteins responsible
for removing heme get saturated and heme can exert its inflammatory
effects."

a(CHEBI:heme) -> path(MESH:Inflammation)

SET Evidence = "Hemolysis can happen due to ischemia/reperfusion, SCD or
Î²-thalassemia."

path(MESH:Ischemia) pos path(MESH:Hemolysis) 
path(MESH:"Anemia, Sickle Cell") pos path(MESH:Hemolysis) 
path(MESH:Thalassemia) pos path(MESH:Hemolysis) 

SET Evidence = "Hemolysis increases the concentration of Hb
which, under oxidative stress, releases free heme."

path(MESH:Hemolysis) pos p(HGNC:HBB)
p(HGNC:HBB) -> a(CHEBI:heme)

SET Evidence = "Heme activates
neutrophils and endothelial cells, by ROS generation."

a(CHEBI:heme) -> a(MESH:"Reactive Oxygen Species")
a(MESH:"Reactive Oxygen Species") -> bp(MESH:"Neutrophil Activation")
a(MESH:"Reactive Oxygen Species") -> bp(GO:"endothelial cell activation")

SET Evidence = "In
endothelial cells, heme induces TLR4-dependent degranulation of
WeibelâPalade bodies and P-selectins and VWF release."

a(CHEBI:heme) -> p(HGNC:SELP)
a(CHEBI:heme) -> p(HGNC:VWF)

SET Evidence = "The VWF is
prothrombotic and can increase the adhesion of erythrocytes to the
endothelium."

p(HGNC:VWF) pos path(MESH:Thrombosis)

SET Evidence = "Heme also induces the expression of the adhesion
molecules ICAM-1, VCAM-1, and E-selectins."

a(CHEBI:heme) -> p(HGNC:ICAM1)
a(CHEBI:heme) -> p(HGNC:VCAM1)
a(CHEBI:heme) -> p(HGNC:SELE)

SET Evidence = " Depending on
the extension of the vaso-occlusion, some tissues may experience
hypoxia and damage."

path(HM:"vaso-occlusive crisis") pos path(MESH:Hypoxia)

SET Evidence = " Vaso-occlusion of the lung microvasculature may
result in the development of the ACS through the infarction of the lung
parenchyma."

path(HM:"vaso-occlusive crisis") pos path(MESH:"Acute Chest Syndrome")

SET Evidence = "Therefore, it is clear that heme triggers 
ROS-induced sensitization of macrophages to TNFR-mediated 
cell death through RIP1 and RIP3 activation to promote 
necroptosis (Figure 2)."

a(CHEBI:heme) -> bp(GO:"necroptotic process")

SET Evidence = "Heme-induced necroptosis is reversed by deferoxamine, a Fe chelator."

a(CHEBI:"desferrioxamine B") neg bp(GO:"necroptotic process")

SET Evidence = "Stimulation of astrocytes with heme, 
as a model of hemorrhagic injury, causes cell death 
with characteristics of programed necrosis including 
the loss of plasma membrane integrity, reversion by 
necrostatin-1, a selective inhibitor of RIP1, and 
by antioxidants (Laird et al., 2008)."

a(MESH:"necrostatin-1") -| p(HGNC:RIPK1) 

SET Evidence = "In fact, TLR4 is involved in intracerebral 
hemorrhage (ICH) induced by heme (Lin et al., 2012)."

SET MeSHDisease = "Cerebral Hemorrhage"
a(CHEBI:heme) -> p(HGNC:TLR4)

SET Evidence = "Moreover, heme induces apoptosis in human 
brain vascular endothelial cells (HBVEC) by STAT3 
(signal transducer and activator of transcription 3)-dependent 
activation of matrix metallopeptidase 3 (MMP3; Liu et al., 2013)."

a(CHEBI:heme) -> bp(MESH:Apoptosis)

SET Evidence = "Importantly, increased expression of FtH also 
protects different cell types from the cytotoxic effects 
of heme, TNF or heme and TNF (Balla et al., 1992; 
Berberat et al., 2003; Cozzi et al., 2003; Gozzelino et al., 2012)."

p(HGNC:FTH1) -| a(HM:"Heme cytotoxicity")

SET Evidence = "The antioxidant property of FtH blocks TNF-induced JNK 
activation, reducing cell death (Pham et al., 2004; Kamata et 
al., 2005; Gozzelino et al., 2012)."

p(HGNC:FTH1) -| p(HGNC:MAPK8)

SET Evidence = "Hb synergizes with LPS enhancing 
the production of pro-inflammatory cytokines 
by macrophages (Yang et al., 2002). "

complex(p(HGNC:HBB), a(MESH:Lipopolysaccharides)) -> a(MESH:Cytokines)

SET Evidence = " In vivo, injection of heme and LPS 
induces a significant increase in the concentrations 
of TNF and IL-6 when compared to the challenge 
with LPS alone (Fernandez et al., 2010)."

complex(a(CHEBI:heme), a(MESH:Lipopolysaccharides)) -> p(HGNC:TNF)
complex(a(CHEBI:heme), a(MESH:Lipopolysaccharides)) -> p(HGNC:IL6)

SET Evidence = "Atypical hemolytic uremic syndrome (aHUS) 
is characterized by an over activation of the complement 
alternative pathway (CAP) due to genetic and acquired 
abnormalities (Noris and Remuzzi, 2009)."

bp(GO:"complement activation, alternative pathway") pos  path(MESH:"Atypical Hemolytic Uremic Syndrome")

SET Evidence = "In fact, Tlr4-/- or anti-TLR4 treatment suppresses heme-induced neuroinflammation, edema, and neurologic deficit. "

p(HGNC:TLR4) pos path(MESH:"Neurogenic Inflammation")
p(HGNC:TLR4) pos path(MESH:"Brain Edema")

SET Evidence = ". Interestingly, NLRP3 knockdown and mROS inhibitors reduce brain 
edema and improve neurological functions (Ma et al., 2014)."

p(HGNC:NLRP3) pos path(MESH:"Brain Edema")

SET Evidence = "Low-density lipoprotein is the major lipid involved in plaque formation."

a(CHEBI:"low-density lipoprotein") pos path(MESH:"Plaque, Atherosclerotic")

SET Evidence = "Indeed, TLRs and NLRP3 have been associated with atherosclerosis development."

p(HGNC:NLRP3) -> path(MESH:Atherosclerosis)
p(HGNC:TLR4) -> path(MESH:Atherosclerosis)
p(HGNC:TLR6) -> path(MESH:Atherosclerosis)

SET Evidence = "In fact, heme-induced LDL oxidation is 
highly cytotoxic for endothelial cells and LDL oxidation 
seems to be mediated by Fe (Jeney et al., 2002; Nagy et al., 2010). "

a(CHEBI:heme) pos a(CHEBI:"oxidised LDL")

SET Evidence = "Interestingly, a 6-year-old patient with HO-1 deficiency 
experienced a severe atherosclerotic pathology (Yachie et al., 1999). "

p(HGNC:HMOX1) -| path(MESH:Atherosclerosis)

SET Evidence = "After hemolysis, sustained interaction between 
Hb and ROS can lead to ferrylhemoglobin (ferrylHb) formation, 
which is characterized by an increase in the Fe oxidative 
state to Fe+4 (Harel and Kanner, 1988; Patel et al., 1996). "

complex(p(HGNC:HBB), a(MESH:"Reactive Oxygen Species")) -> a(MESH:ferrylhemoglobin)

SET Evidence = "Similarly to heme, ferrylHb activates endothelial 
cells through NFÎºB activation (Silva et al., 2009)."

a(MESH:ferrylhemoglobin) -> bp(GO:"endothelial cell activation")

SET Evidence = " Moreover, ferrylHb is unable to induce cytokine secretion by endothelial cells (Silva et al., 2009), 
another difference to heme which induces IL-8 production (Natarajan et al., 2007). "

a(MESH:ferrylhemoglobin) causesNoChange a(MESH:Cytokines)
a(MESH:ferrylhemoglobin) -> p(HGNC:CXCL8)

SET Evidence = "Like MetHb, ferrylHb is unstable and releases free heme to 
further increase oxLDL formation (Potor et al., 2013)."

a(MESH:ferrylhemoglobin) -> a(CHEBI:heme)

SET Evidence = " LXR-Î² protects against lipid overload 
by activating a lipid exportation program regulated by 
proteins such as LXR-Î± and ATP binding cassette 
transporter A1 (ABCA1), preventing foam cells formation. "

p(HGNC:NR1H2) pos bp(GO:"lipid homeostasis")

UNSET TextLocation
##################